Telemedicine After the Boom: The Rules Get Real
The pandemic made video doctor visits normal. Now regulators are deciding which parts of the experiment were worth keeping.
In the space of a few months in 2020, telemedicine went from a niche service to a default. Regulators suspended rules, insurers agreed to pay, and patients discovered that a surprising amount of medicine does not require being in the same room as a doctor. Usage has since fallen back from the peak, but it has stabilised far above pre-pandemic levels. The emergency is over; the policy fight is what remains.
The core questions are the same everywhere. Should a video visit be paid the same as an in-person one? Can a doctor licensed in one jurisdiction treat a patient in another? Which prescriptions can be written without a physical examination? And what standards apply to the wave of direct-to-consumer platforms that pair consultations with their own pharmacies?
The evidence has clarified some things. For mental health, follow-up care, chronic disease management and dermatology, remote care works well and patients strongly prefer it. For first diagnoses, anything requiring touch, and older patients with complex conditions, in-person care retains clear advantages. The sensible consensus forming in most health systems is hybrid: telemedicine as a front door and a follow-up channel, not a replacement.
Payment rules are the real lever. Where insurers pay equally for video and in-person visits, telemedicine thrives; where they pay less, providers quietly steer patients back to the clinic. Several US states have made pandemic-era payment parity permanent; others have let it lapse. India formalised telemedicine practice guidelines in 2020, giving the sector legal footing, and platforms there have grown rapidly — though enforcement of prescribing rules remains uneven.
The sharpest regulatory concern is the rise of vertically integrated platforms: apps that diagnose, prescribe and sell the medication, profiting at each step. The model is convenient and has widened access, but it creates an obvious incentive to prescribe. Regulators in several countries are now asking whether a consultation that lasts ninety seconds and always ends in a sale is really a consultation.
There is also an access paradox. Telemedicine was supposed to reach the underserved — rural patients, people without transport, those who cannot take a day off work for an appointment. It does, sometimes. But it also demands a smartphone, a data connection, privacy at home and digital literacy. The populations with the worst healthcare access often have the worst connectivity too. Done well, telemedicine narrows gaps; done lazily, it moves the queue rather than shortening it.
For patients, the practical guidance is simple: telemedicine is excellent for the known and the routine, weaker for the new and the ambiguous, and any platform that sells what it prescribes deserves an extra question.
What is not yet known is where the liability line settles. When a remote consultation misses something an examination would have caught, who is responsible — the doctor, the platform, the algorithm that triaged the case? Court systems are only beginning to work that out, and their answers will shape the industry more than any technology will.
Every claim above is sourced to a document, a named person, or a record we hold. Where we could not verify a claim, we say so. Read our standards and corrections policy →